Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 18 February, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo

Suven Pharmaceuticals Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: February 17, 2025, 10:15 pm

Market Cap 28,534 Cr.
Current Price 1,119
High / Low 1,360/597
Stock P/E102
Book Value 77.7
Dividend Yield0.00 %
ROCE18.8 %
ROE14.1 %
Face Value 1.00
PEG Ratio-95.62

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Suven Pharmaceuticals Ltd

Competitors of Suven Pharmaceuticals Ltd

Stock Name Market Cap Current Price High / Low Stock P/E Book Value Dividend Yield ROCE ROE Face Value
MPS Pharmaa Ltd 7.63 Cr. 3.99 4.33/3.05 0.800.00 %9.15 %34.9 % 10.0
Gujarat Themis Biosyn Ltd 2,503 Cr. 230 390/21647.5 20.50.29 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 53.9 Cr. 72.7 94.9/30.218.3 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 39.1 Cr. 26.7 28.6/8.7439.9 6.640.00 %2.65 %2.08 % 10.0
Godavari Drugs Ltd 65.8 Cr. 87.4 155/82.210.6 55.40.00 %14.4 %15.5 % 10.0
Industry Average17,575.89 Cr1,064.5843.35185.200.36%16.18%16.43%6.27

All Competitor Stocks of Suven Pharmaceuticals Ltd

Quarterly Result

MetricMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
Sales 259264301392364339278354369348231220253
Expenses 165149179206207188179207198181133154180
Operating Profit 94115122186157151100147172167986673
OPM % 36%43%40%48%43%45%36%41%47%48%42%30%29%
Other Income 22292265171111131111201417
Interest 2211210151022
Depreciation 89911101212121213121317
Profit before tax 105133134239161149981461661641056571
Tax % 21%21%28%33%43%28%27%26%25%26%25%29%25%
Net Profit 83105971609210872108124121804753
EPS in Rs 3.274.133.816.293.604.222.834.234.874.743.131.842.10

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Sales 3788341,0101,3201,3401,051
Expenses 206449567738766645
Operating Profit 172385443582574406
OPM % 45%46%44%44%43%39%
Other Income 166681334662
Interest 323129137
Depreciation 122432394855
Profit before tax 158405468668560406
Tax % 31%22%23%32%27%26%
Net Profit 109317362454411300
EPS in Rs 5,463.5012.4514.2317.8316.1611.80
Dividend Payout % 0%20%14%28%37%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)190.83%14.20%25.41%-9.47%-27.01%
Change in YoY Net Profit Growth (%)0.00%-176.63%11.22%-34.89%-17.54%

Suven Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2019-2020 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:%
5 Years:23%
3 Years:1%
TTM:-10%
Compounded Profit Growth
10 Years:%
5 Years:20%
3 Years:-9%
TTM:-25%
Stock Price CAGR
10 Years:%
5 Years:%
3 Years:27%
1 Year:66%
Return on Equity
10 Years:%
5 Years:26%
3 Years:22%
Last Year:14%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 7:33 pm

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital 0.00132525252525
Reserves 5788321,1551,5021,7102,0251,953
Borrowings 8318614397706539
Other Liabilities 123142151205160138488
Total Liabilities 7831,1731,4741,8301,9662,2542,506
Fixed Assets 271357441534663670923
CWIP 1111029630165179241
Investments 7338542598536904751
Other Assets 394376395667601501590
Total Assets 7831,1731,4741,8301,9662,2542,506

Reserves and Borrowings Chart

Cash Flow

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +50407383330457358
Cash from Investing Activity +-65-413-311-136-195-362
Cash from Financing Activity +267-76-156-242-14
Net Cash Flow111-53720-18

Free Cash Flow

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow89.00199.00300.00485.00504.00341.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days1425137653046
Inventory Days556278243259279268
Days Payable190113100976349
Cash Conversion Cycle509217180228247265
Working Capital Days28510595126117130
ROCE %50%40%41%32%19%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Promoters60.00%60.00%60.00%60.00%60.00%60.00%60.00%60.00%60.00%60.00%50.10%50.10%
FIIs8.03%8.25%8.56%8.49%7.58%8.11%9.47%9.50%10.01%10.14%9.54%9.80%
DIIs5.81%5.93%6.56%6.96%10.87%11.36%11.43%10.63%14.13%15.94%17.24%17.42%
Government0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.01%0.01%0.01%0.01%0.01%
Public26.16%25.82%24.88%24.55%21.56%20.55%19.10%19.88%15.85%13.93%23.11%22.67%
No. of Shareholders96,53286,44785,72586,08882,57779,41272,88572,16773,71570,05268,93265,777

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
UTI Flexi Cap Fund4,969,2141.36359.172,510,6902025-02-1697.92%
DSP Healthcare Fund2,510,6908.97181.472,510,6902025-02-160%
HSBC Small Cap Fund - Regular Plan2,298,0851.26166.112,510,6902025-02-16-8.47%
DSP ELSS Tax Saver Fund2,069,4531.1149.582,510,6902025-02-16-17.57%
Tata Small Cap Fund2,000,0002.48144.562,510,6902025-02-16-20.34%
UTI Value Fund1,678,4991.43121.322,510,6902025-02-16-33.15%
Canara Robeco Small Cap Fund1,675,9831.32121.142,510,6902025-02-16-33.25%
DSP Equity Opportunities Fund1,539,7021.07111.292,510,6902025-02-16-38.67%
DSP Flexi Cap Fund1,355,0020.9797.942,510,6902025-02-16-46.03%
HSBC Midcap Fund1,340,2001.0596.872,510,6902025-02-16-46.62%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue 1.001.001.001.001.00
Basic EPS (Rs.) 11.8016.1617.8314.2324.91
Diluted EPS (Rs.) 11.8016.1617.8314.2324.91
Cash EPS (Rs.) 13.9418.0317.7513.3722.99
Book Value[Excl.RevalReserv]/Share (Rs.) 80.5668.1659.9946.3966.37
Book Value[Incl.RevalReserv]/Share (Rs.) 80.5668.1659.9946.3966.37
Revenue From Operations / Share (Rs.) 41.3052.6551.8639.6665.51
PBDIT / Share (Rs.) 18.3724.0826.3917.8631.68
PBIT / Share (Rs.) 16.2322.2024.8516.6229.81
PBT / Share (Rs.) 15.9421.9924.6116.2627.99
Net Profit / Share (Rs.) 11.8016.1616.2112.1221.12
NP After MI And SOA / Share (Rs.)11.8016.1617.8314.2324.91
PBDIT Margin (%) 44.4845.7250.8845.0348.36
PBIT Margin (%) 39.2942.1647.9241.9045.49
PBT Margin (%) 38.5841.7647.4540.9942.73
Net Profit Margin (%) 28.5630.6831.2530.5632.23
NP After MI And SOA Margin (%)28.5630.6834.3735.8838.01
Return on Networth / Equity (%) 14.6423.7029.7130.6837.52
Return on Capital Employeed (%) 19.2431.2739.0733.7139.01
Return On Assets (%) 13.3220.9224.8024.5727.02
Long Term Debt / Equity (X) 0.000.000.010.030.10
Total Debt / Equity (X) 0.010.040.060.110.21
Asset Turnover Ratio (%) 0.490.700.800.790.88
Current Ratio (X) 11.826.375.362.571.95
Quick Ratio (X) 9.654.404.021.661.08
Inventory Turnover Ratio (X) 0.971.441.901.651.45
Dividend Payout Ratio (NP) (%) 0.0049.5122.437.0220.07
Dividend Payout Ratio (CP) (%) 0.0044.3620.656.4618.67
Earning Retention Ratio (%) 0.0050.4977.5792.9879.93
Cash Earning Retention Ratio (%) 0.0055.6479.3593.5481.33
Interest Coverage Ratio (X) 62.77112.74107.8249.7317.48
Interest Coverage Ratio (Post Tax) (X) 41.3076.6667.2334.7512.65
Enterprise Value (Cr.) 17211.9412039.3615779.1112742.732735.31
EV / Net Operating Revenue (X) 16.378.9811.9512.623.28
EV / EBITDA (X) 36.8019.6423.4928.026.78
MarketCap / Net Operating Revenue (X) 16.388.9811.9212.493.08
Retention Ratios (%) 0.0050.4877.5692.9779.92
Price / BV (X) 8.406.9310.3010.683.04
Price / Net Operating Revenue (X) 16.388.9811.9212.493.08
EarningsYield 0.010.030.020.020.12

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Suven Pharmaceuticals Ltd as of February 18, 2025 is: ₹911.86

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of February 18, 2025, Suven Pharmaceuticals Ltd is Overvalued by 18.51% compared to the current share price ₹1,119.00

Intrinsic Value of Suven Pharmaceuticals Ltd as of February 18, 2025 is: 902.13

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of February 18, 2025, Suven Pharmaceuticals Ltd is Overvalued by 19.38% compared to the current share price ₹1,119.00

Last 5 Year EPS CAGR: -1.07%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 30.33%, which is a positive sign.
  2. The company has higher reserves (1,393.57 cr) compared to borrowings (97.57 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (202.67 cr) and profit (444.17 cr) over the years.
  1. The stock has a high average Working Capital Days of 143.00, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 274.33, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Suven Pharmaceuticals Ltd:
    1. Net Profit Margin: 28.56%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 19.24% (Industry Average ROCE: 16.05%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 14.64% (Industry Average ROE: 15.89%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 41.3
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 9.65
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 102 (Industry average Stock P/E: 35.11)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.01
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Suven Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 06/11/2018 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24299MH2018PLC422236 and registration number is 422236. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 1024.99 Cr. and Equity Capital is Rs. 25.46 Cr. for the Year ended 31/03/2024.
INDUSTRYADDRESSCONTACT
Pharmaceuticals215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Mumbai Maharashtra 400093info@suvenpharm.com
www.suvenpharm.com
Management
NamePosition Held
Mr. Annaswamy VaidheeshExecutive Chairperson
Dr. V Prasada RajuManaging Director
Mr. Pankaj PatwariNon Executive Director
Ms. Shweta JalanNon Executive Director
Ms. Matangi GowrishankarIndependent Director
Mr. Vinod RaoIndependent Director
Mr. K G AnanthakrishnanIndependent Director
Mr. Pravin Rao Udhyavara BhadyaIndependent Director

FAQ

What is Suven Pharmaceuticals Ltd's true worth and is it a good investment?

Let's break down Suven Pharmaceuticals Ltd's valuation simply:

We calculate intrinsic value using the PE Ratio Method - comparing the company's current price-to-earnings ratio with its historical average and industry peers. Think of it like checking if a stock is "on sale" compared to its typical pricing.

As of 18 February 2025:

  • Calculated Fair Value: ₹911.86
  • Current Market Price: ₹1,119.00
  • Variance: 18.51% lower

This suggests Suven Pharmaceuticals Ltd is currently overvalued by 18.51%. For context:

  • Market Cap: 28,534 Cr.
  • 52-Week Range: 1,360/597
  • Reserves (Sep 2024): ₹1,953 Cr
  • Liabilities: 2,506 Cr

Remember: The PE method gives a snapshot based on earnings multiples. While useful for quick comparisons, investors should also consider growth prospects, industry trends, and economic conditions. This calculation assumes historical PE ratios remain relevant - always verify with current market dynamics.

What is the Market Cap of Suven Pharmaceuticals Ltd?

The Market Cap of Suven Pharmaceuticals Ltd is 28,534 Cr..

What is the current Stock Price of Suven Pharmaceuticals Ltd as on 18 February 2025?

The current stock price of Suven Pharmaceuticals Ltd as on 18 February 2025 is ₹1,119.

What is the High / Low of Suven Pharmaceuticals Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Suven Pharmaceuticals Ltd stocks is 1,360/597.

What is the Stock P/E of Suven Pharmaceuticals Ltd?

The Stock P/E of Suven Pharmaceuticals Ltd is 102.

What is the Book Value of Suven Pharmaceuticals Ltd?

The Book Value of Suven Pharmaceuticals Ltd is 77.7.

What is the Dividend Yield of Suven Pharmaceuticals Ltd?

The Dividend Yield of Suven Pharmaceuticals Ltd is 0.00 %.

What is the ROCE of Suven Pharmaceuticals Ltd?

The ROCE of Suven Pharmaceuticals Ltd is 18.8 %.

What is the ROE of Suven Pharmaceuticals Ltd?

The ROE of Suven Pharmaceuticals Ltd is 14.1 %.

What is the Face Value of Suven Pharmaceuticals Ltd?

The Face Value of Suven Pharmaceuticals Ltd is 1.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Suven Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE